Alpha-1 Proteinase Inhibitor Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alpha 1-proteinase inhibitor (API) deficiency, which leads to conditions like emphysema and liver disease, are limited, particularly in maintaining stable API plasma bioavailability and preventing lung tissue destruction due to uninhibited proteases.
Innovation Solution
A composition comprising alpha 1-proteinase inhibitor (API) combined with at least one amino acid, such as alanine, glycine, or sucrose, is developed to enhance stability and bioavailability, potentially administered through various pharmaceutical forms like aerosols or injectables, to effectively inhibit proteases and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If API is administered alone, then the composition is simple, but the stability and bioavailability of API are insufficient
Solution Approach 1:
Amino acids serve as intermediary substances that mediate between the API and the biological environment. They stabilize the API protein structure, prevent aggregation, and enhance bioavailability without requiring complex formulation systems. The amino acids act as protective agents that interface with the API's vulnerable regions.
Solution Approach 2:
The invention changes the chemical composition parameters of the API formulation by introducing specific amino acids. This modifies the physical-chemical environment around the API, altering its stability profile and bioavailability characteristics without fundamentally changing the API structure itself.
2Quantity of substance
If API concentration is increased to achieve therapeutic levels, then therapeutic efficacy improves, but protein aggregation and instability increase
Solution Approach 1:
Amino acids function as protective intermediaries that surround and stabilize API molecules even at high concentrations. They prevent direct protein-protein interactions that lead to aggregation, allowing therapeutic levels of API to be maintained without compromising stability.
Solution Approach 2:
The amino acids provide preemptive protection against aggregation and degradation pathways. By being present in the formulation beforehand, they cushion the API against destabilizing forces that would otherwise become significant at therapeutic concentrations.
3Reliability
If no stabilizing agents are used, then the composition remains simple, but API degradation and loss of activity occur
Solution Approach 1:
Amino acids act as intermediary protective agents that prevent direct exposure of API to degrading conditions. They form a protective environment around the API, shielding it from oxidative damage, proteolytic cleavage, and other degradation pathways without requiring complex stabilizing systems.
4Quantity of substance
If API is administered without enhancement, then administration is straightforward, but plasma bioavailability levels are insufficient
Solution Approach 1:
Amino acids serve as mediators that enhance API absorption and distribution in the plasma. They facilitate API solubility and prevent premature clearance, thereby increasing bioavailability without requiring complex delivery systems or adjuvants.
Data Source
AI summary
The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.